Virtici LLC, a life science innovation and product development company, today announced that it has been awarded a Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to advance VTC-880, a first-in-class peptide for the prevention and treatment of periodontitis.

Rise Therapeutics, a biopharmaceutical company developing precision immunotherapies, today announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference in San Diego on May 6th.

Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780. This is Rise Therapeutics’ fourth clinical program to enter patient clinical testing. For separate products, other clinical studies are ongoing for the treatment of ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.

Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies will now initiate the planned dose expansion stages to enroll additional patients at fixed doses.

Celdara Medical today celebrates the extraordinary contributions of Lita Nelsen as she retires from our Board of Directors after a decade of transformative leadership and visionary guidance. In honor of her unparalleled impact on the field of technology transfer, and her many contributions to our company, Celdara Medical is proud to announce the creation of the Lita Nelsen Prize.

Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health (NIH) to enable infrastructure improvement that will scale GMP production and accelerate quality assurance (QA) and quality control (QC), significantly enhancing its biologics drug manufacturing capabilities.